Epilepsy

Zogenix’s fenfluramine (Fintepla) appears to provide durable and profound reductions in monthly convulsive seizure frequency for those with Dravet syndrome out to 3 years.

The initial study results may provide the basis for future evaluation as a step towards patient empowerment and objective epilepsy diagnostics for broad application.

The neurologist from Cleveland Clinic discussed initial data from Study 410 and patient compliance rates with perampanel treatment.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending December 4, 2020.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health detailed his study from AES 2020 on using wristband sensor data to forecast seizures.

High retention rates and number of patients remaining seizure-free for prolonged periods indicated the efficacy of cenobamate in treating focal seizures.

Fenfluramine was particularly effective in reducing generalized tonic-clonic seizure frequency in patients with Lennox-Gastaut syndrome, with a push for regulatory submission in the future.

High compliance rates and well-tolerance of perampanel indicate its efficacy as a treatment for partial onset seizures.

The pediatric neurologist at Montefiore Health System provided her thoughts on the importance of Infantile Spasms Awareness Week.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center sat down to discuss a multitude of topics surrounding Infantile Spasms Awareness Week.

In this interview, Patrick Landazuri, MD, discusses the validity of laser ablation as an option for epilepsy surgery.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.

The section chief of pediatric neurology at Nationwide Children’s Hospital discussed his experience using some of the approved medications for patients with Lennox-Gastaut syndrome.

The professor of neurology at the NYU Langone Grossman School of Medicine detailed the ways the COVID-19 pandemic impacted mental health of frontline clinicians.

The vice president of Clinical Research at Eisai detailed why lorcaserin’s formula made it suitable for treating patients with Dravet syndrome.

In this interview, Patrick Landazuri, MD, shares an in-depth look at his investigations into the safety and efficacy of laser ablation.

A Q&A from the Mayo Clinic dives into the methods to treat drug-resistant epilepsy that aren't medication based.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center detailed challenges faced by children with infantile spasms and how the spasms evolve later in life.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 20, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Paul Fisher, MD, and Gerald Grant, MD, FACS.

An overview of the NeurologyLive tweet chat honoring National Epilepsy Awareness Month, featuring highlighted contributions from the medical community.

The vice president of Clinical Research at Eisai provides updates on the MOMENTUM trials which will examine lorcaserin as a potential treatment for patients with Dravet syndrome.

This latest FDA indication includes adjunctive therapy for those aged 4 years and older in both the CV and intravenous formulations of the UCB product.